---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-004910"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T05:55:46.423634+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Monopar board: Michael Brown resigns, Lavina Talukdar appointed

## Summary
- Michael J. Brown resigned from the Board effective February 19, 2025.
- Lavina Talukdar appointed to the Board effective February 21, 2025.
- Talukdar also named to Audit, Compensation, Governance, and Plan Administration Committees.
- Talukdar is SVP, Head of Investor Relations at Moderna, with 20+ years of experience.
- She will receive standard compensation for non-employee directors.

## SEC filing metadata
- accession: 0001437749-25-004910
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774925004910/0001437749-25-004910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774925004910/mnpr20250221_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-004910
- JSON: https://secwatch.observer/filing/0001437749-25-004910.json
- Plain text: https://secwatch.observer/filing/0001437749-25-004910.txt

## Key facts
- Executive change
  Lavina Talukdar was appointed as Director at Monopar Therapeutics.
  - Action: appointed
  - Role: Director
  source text: On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774925004910/0001437749-25-004910-index.htm
- Executive change
  Michael J. Brown resigned as Director at Monopar Therapeutics.
  - Action: resigned
  - Role: Director
  source text: Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774925004910/0001437749-25-004910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.